Show simple item record

dc.contributor.authorPurshouse, K
dc.contributor.authorBulbeck, HJ
dc.contributor.authorRooney, AG
dc.contributor.authorNoble, KE
dc.contributor.authorCarruthers, RD
dc.contributor.authorThompson, G
dc.contributor.authorHamerlik, P
dc.contributor.authorYap, C
dc.contributor.authorKurian, KM
dc.contributor.authorJefferies, SJ
dc.contributor.authorLopez, JS
dc.contributor.authorJenkinson, MD
dc.contributor.authorHanemann, CO
dc.contributor.authorStead, LF
dc.coverage.spatialEngland
dc.date.accessioned2024-04-30T15:57:46Z
dc.date.available2024-04-30T15:57:46Z
dc.date.issued2024-04-01
dc.identifier.citationNeuropathology and Applied Neurobiology, 2024, 50 (2), pp. e12979 -
dc.identifier.issn0305-1846
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6217
dc.identifier.eissn1365-2990
dc.identifier.eissn1365-2990
dc.identifier.doi10.1111/nan.12979
dc.identifier.doi10.1111/nan.12979
dc.description.abstractIn 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of funding, to be paralleled with £25m from Cancer Research UK, specifically for neuro-oncology research over the subsequent 5 years. Herein, we review if and how the adult brain tumour research landscape in the United Kingdom has changed over that time and what challenges and bottlenecks remain. We have identified seven universal brain tumour research priorities and three cross-cutting themes, which span the research spectrum from bench to bedside and back again. We discuss the status, challenges and recommendations for each one, specific to the United Kingdom.
dc.formatPrint
dc.format.extente12979 -
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofNeuropathology and Applied Neurobiology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbrain cancer
dc.titleAdult brain tumour research in 2024: Status, challenges and recommendations.
dc.typeJournal Article
dcterms.dateAccepted2024-03-25
dc.date.updated2024-04-16T08:09:55Z
rioxxterms.versionAM
rioxxterms.versionofrecord10.1111/nan.12979
rioxxterms.licenseref.startdate2024-04-01
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38605644
pubs.issue2
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Early Phase Drug Development
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1111/nan.12979
pubs.volume50
icr.researchteamEarly Phase Drug Develop
dc.contributor.icrauthorYap, Christina
icr.provenanceDeposited by Dr Juanita Lopez on 2024-04-16. Deposit type is initial. No. of files: 1. Files: NAN-2024-0026-RESUBMISSIONDv2_CLEAN.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/